Since EU-LIFE's creation in 2014, our member institutes have spun-out over 80 companies, contributing directly to the European innovation ecosystem. EU-LIFE works to make sure that the innovation cycle is strong by providing cutting-edge discoveries coupled to effective valorisation strategies, as well as helping member organisations to be more performant and efficient.

 

Policy work

EU-LIFE contributed to the concept and implementation of the European Innovation Council (EIC), interacting regularly with EIC. Early on, EU-LIFE responded to the European Commission's call for ideas on the EIC in 2016. Afterwards, Jo Bury, member of the EU-LIFE Board of Directors and Managing Director of VIB, was appointed member of the EIC Pilot Advisory Board among 22 exceptional innovators in 2019, and he is still a EIC Ambassador.

EU-LIFE has actively participated in the European Research Area (ERA) as stakeholder and is commited to ERA Action 7. Upgrade EU guidance for a better knowledge valorisation. In addition, EU-LIFE member institutes participated in the communities groups that helped create the Guiding Principles for Knowledge Valorisation and Codes of Practice.

We also interact frequently with innovation leaders of the biotech sector. The EU-LIFE Strategy Meeting 2024 in Copenhagen, for instance, included the 'Fundamental research for a global world' exchange session with Danish biotech, funding and academic stakeholders.

 

Publications

 

Community

The Technology Transfer Working Group (TT WG) gathers tech transfer experts from our member institutes. The group was created to facilitate sharing good practices among these professionals and to provide scientists with knowledge and resources to help them bridge the gap between research and market.

The EU-LIFE Pitching Event is organised annually by the TT WG, with the aim to provide scientists leading translational projects in EU-LIFE research institutions with opportunities to talk confidentially to venture capitalists, receive feedback on their ideas, and gain insight about how to establish a new venture. Since 2021, it is organised virtually to facilitate participation and maximize exchange, with a total of 22 translational projects from EU-LIFE member institutes in 10 European countries pitched to over 60 venture capitalists and pharmaceutical company technology scouts on topics such as oncology, neurodegeneration, pulmonary diseases, agrobiotech and diagnostics. Based on data from the 2022 and 2023 pitching events, 3 companies have been founded and several other companies are under due diligence with venture capital investors. 

 

Other actions & outreach